{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=20",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 20596,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T07:55:43.713Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00387959",
      "title": "Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2006-07",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-02-01",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00387959"
    },
    {
      "nct_id": "NCT04338659",
      "title": "A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Tumors Lymphomas"
      ],
      "interventions": [
        {
          "name": "IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-01-14",
      "completion_date": "2023-02-28",
      "has_results": false,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Westwood, Kansas • Jackson, Mississippi + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04338659"
    },
    {
      "nct_id": "NCT02200380",
      "title": "A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "For Donors",
        "Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling",
        "For Recipients",
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Myelogenous Leukemia (CML)",
        "Non-Hodgkins Lymphoma (NHL)",
        "Hodgkins Disease (HD)",
        "Chronic Lymphocytic Leukemia (CLL)"
      ],
      "interventions": [
        {
          "name": "CDX-301",
          "type": "DRUG"
        },
        {
          "name": "CDX-301 and plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-07",
      "completion_date": "2016-04-13",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02200380"
    },
    {
      "nct_id": "NCT01853917",
      "title": "Evaluation of Barriers to Postpartum Care in HIV Infected Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection",
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "questionaires and structured interviews",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2012-01",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2014-12-04",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853917"
    },
    {
      "nct_id": "NCT00273689",
      "title": "Exercise Induced Bronchospasm in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Exercise Induced Bronchospasm"
      ],
      "interventions": [
        {
          "name": "montelukast vs pretreatment with albuterol",
          "type": "DRUG"
        },
        {
          "name": "montelukast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 13,
      "start_date": "2005-12",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2008-05-07",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273689"
    },
    {
      "nct_id": "NCT03201250",
      "title": "Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-02-21",
      "completion_date": "2021-04-12",
      "has_results": true,
      "last_update_posted_date": "2023-09-08",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 2,
      "location_summary": "Omaha, Nebraska • Houston, Texas",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03201250"
    },
    {
      "nct_id": "NCT01902290",
      "title": "Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Brodalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 421,
      "start_date": "2013-05-22",
      "completion_date": "2015-05-15",
      "has_results": true,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01902290"
    },
    {
      "nct_id": "NCT04247620",
      "title": "DiaBetter Together for Young Adults With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "DiaBetter Together",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Peer Mentor Delivery",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "17 Years to 35 Years"
      },
      "enrollment_count": 144,
      "start_date": "2020-12-15",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04247620"
    },
    {
      "nct_id": "NCT01590459",
      "title": "24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "VX-509",
          "type": "DRUG"
        },
        {
          "name": "VX-509 matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 359,
      "start_date": "2012-04",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-11-20",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590459"
    },
    {
      "nct_id": "NCT07283640",
      "title": "A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blinatumomab",
        "Revumenib",
        "Lymphoblastic Leukemia",
        "KMT2A-rearranged"
      ],
      "interventions": [
        {
          "name": "Revumenib",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-11-18",
      "completion_date": "2031-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-18T07:55:43.713Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07283640"
    }
  ]
}